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ABSTRACT 30 
Background: Hypoxia imaging is a promising tool for targeted therapy but the links between 31 
imaging features and underlying molecular characteristics of the tumour have not been 32 
investigated. The aim of this study was to compare hypoxia biomarkers and gene expression 33 
in oropharyngeal squamous cell carcinoma (OPSCC) diagnostic biopsies with hypoxia 34 
imaged with 64Cu-ATSM PET/CT. 35 
Methods: 64Cu-ATSM imaging, molecular and clinical data were obtained for 15 patients. 36 
Primary tumour SUVmax, tumour to muscle ratio (TMR) and hypoxic volume were tested for 37 
association with reported hypoxia gene signatures in diagnostic biopsies. A putative gene 38 
signature for hypoxia in OPSCCs (hypoxic volume-associated gene signature, HVS) was 39 
derived. 40 
Results: Hypoxic volume was significantly associated with a reported hypoxia gene 41 
signature (rho=0.57, P=0.045), but SUVmax and TMR were not. Immunohistochemical 42 
staining with the hypoxia marker carbonic anhydrase 9 (CA9) was associated with a gene 43 
expression hypoxia response (rho=0.63, P=0.01). 16 genes were positively and 5 genes 44 
negatively associated with hypoxic volume (adjusted P<0.1; eight genes had adjusted 45 
P<0.05; HVS). This signature was associated with inferior 3-year progression-free survival 46 
(HR=1.5 [1.0-2.2], P=0.047) in an independent patient cohort. 47 
Conclusion: 64Cu-ATSM defined hypoxic volume was associated with underlying hypoxia 48 
gene expression response. A 21-gene signature derived from hypoxic volume from patients 49 
with OPSCCs in our study may be linked to progression-free survival. 50 
 51 
Keywords (3 to 12): Head and neck cancers; oropharyngeal carcinoma; PET/CT imaging; 52 
hypoxia; RNA-sequencing. 53 
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ABBREVIATIONS 59 
FFPE: formalin-fixed, paraffin-embedded 60 
HVS: hypoxic volume-associated gene signature 61 
OPSCC: Oropharyngeal squamous cell carcinoma 62 
SUV: Standardised uptake value 63 
TMR: Tumour to muscle ratio 64 
 65 
 66 
  67 
  
INTRODUCTION 68 
 69 
Hypoxia has been extensively investigated in head and neck squamous cell carcinoma 70 
(HNSCC) and the association with poor outcome is well known (Nordsmark et al, 2005). A 71 
number of therapeutic interventions can target global or focal hypoxia in tumours 72 
(Hendrickson et al, 2011; Rischin et al, 2010), however the selection of patients with hypoxic 73 
tumours who would benefit from these interventions has been the major limiting factor for 74 
translation into clinical practice.  75 
 Accurate detection and quantification of hypoxic tumours is essential to identify 76 
patients who have aggressive, treatment resistant disease. Various methods have been 77 
investigated but with inconsistent and sometimes conflicting results, lacking the sensitivity 78 
and specificity needed for clinical utility (Aebersold et al, 2001; Overgaard et al, 2005). 79 
Hypoxic gene expression signatures from biopsy samples could have predictive value 80 
(Toustrup et al, 2011; Winter et al, 2007) but are not able to quantify hypoxia or provide 81 
information on its the spatial distribution within tumours. Combining hypoxic gene signatures 82 
and 64Cu-ATSM PET imaging biomarkers may enable a more comprehensive assessment of 83 
the hypoxic status of tumours.  84 
 64Cu-ATSM is a PET radiotracer that has been shown to accumulate in hypoxic and 85 
other conditions of mitochondrial dysfunction (Donnelly et al, 2012; Lewis et al, 1999). 86 
Although the exact mechanism has not been elucidated and uptake may be dependent on 87 
cell or tumour type, clinical studies have clearly demonstrated the potential as an imaging 88 
biomarker that warrants further investigation, especially in HNSCC, with clear advantages 89 
over the nitroimidazole-based hypoxia tracers (Grassi et al, 2014; Minagawa et al, 2011; 90 
Sato et al, 2014).  91 
 Our study hypothesis was that hypoxia gene signatures from diagnostic FFPE biopsy 92 
samples would be associated with uptake of 64Cu-ATSM in patients with OPSCC, and a 93 
signature could be developed to identify patients with OPSCC who would benefit from further 94 
  
investigation with hypoxia imaging. This would, in turn, provide more information on the level 95 
and distribution of hypoxic regions, which could potentially guide treatment.  96 
  
MATERIALS AND METHODS 97 
 98 
Patients 99 
Fifteen patients with newly diagnosed histologically proven stage III-IV squamous cell 100 
carcinoma of the oropharynx to be treated with standard radical concomitant chemoradiation 101 
were prospectively recruited as part of an initial pilot phase of the study. HPV status was 102 
determined by p16 IHC and by in-situ hybridisation for high risk subtype DNA. Patients 103 
received a static 64Cu-ATSM PET/CT scan of the head and neck approximately 1 week prior 104 
to the start of their treatment. Time between biopsy and imaging was recorded (Table 1, 105 
Supplementary Figure S7). On inspection of clinical follow-up there was one reported death 106 
(not disease-specific) and all other patients so far have no recurrence (median time-to-follow 107 
up, 24 months). Research Ethics Committee approval was obtained for the study (reference 108 
12/LO/1123) and all patients gave written and voluntary consent. 109 
 110 
Image acquisition and analysis 111 
Detailed methods for image acquisition and analysis are provided as Supplementary 112 
Information. In summary, patients were injected with 545 ± 27 (range 486 - 577) MBq of 113 
64Cu-ATSM followed by an uptake period of 60 minutes. The first patient acquisition was 114 
performed on a GE Discovery VCT PET/CT scanner (General Electric Medical Systems, 115 
Waukesha, Wisconsin, USA). All subsequent patients were imaged on the GE Discovery 116 
710 PET/CT scanner. The 64Cu-ATSM PET/CT images were interpreted by a nuclear 117 
medicine physician and clinical oncologist using Hermes Hybrid Viewer version 2.2C 118 
(Hermes Medical Solutions, Stockholm, Sweden). PET uptake was assessed semi-119 
quantitatively using standardised uptake values (SUV) normalised to patient body weight  120 
determined using the following equation: 121 
 SUVbw = 64Cu-ATSM activity concentration measured in the tumour (Bq/cc) x 122 
 (patient body weight (kg)/injected activity of 64Cu-ATSM (Bq) decay corrected to  the 123 
 time of injection) x 1000 g/cc 124 
  
Visible lesions on PET with uptake higher than background muscle uptake were considered 125 
hypoxic. Background uptake was evaluated by placing fixed 2.5 cm spheres over bilateral 126 
posterior neck muscles on the CT images to guide correct positioning, copying the spheres 127 
onto the PET images and calculating the average SUVmean. Regions of interest (ROIs) were 128 
outlined in multiple planes using a set zoom, SUV scaling and colour scale. An initial region 129 
was drawn using an automatic segmentation seeded region growing tool on each scan slice 130 
and manually edited. The seeded region growing tool starts with a seed pixel within the 131 
tumour and then adds pixels to the region in all direction. The operator determined the extent 132 
of pixel expansion and final region outlined. ROIs were then summed to create a volume, or 133 
the hypoxic volume. For each primary tumour SUVmax, tumour to muscle ratio (TMR), tumour 134 
SUVmean and hypoxic volume were measured. TMR was determined by the ratio of tumour 135 
SUVmax to the average SUVmean of the posterior neck muscles. 136 
 137 
Immunohistochemistry, RNA extraction, sequencing and analysis 138 
Diagnostic biopsy slides were reviewed by a head and neck pathologist to confirm the 139 
diagnosis, and the tumour outline marked on the slide without further selection. Sections 140 
from FFPE tumour blocks were placed onto slides for immunohistochemical staining for 141 
carbonic anhydrase 9 (CA9), an endogenous marker for hypoxia, as previously described 142 
(Watson et al, 2003). Blocks were then scored with a surgical blade to correspond with the 143 
tumour regions on the slides. Ten micrometre thick sections of the tumour area were cut on 144 
a microtome (minimum 10 sections, minimum tumour area 100 mm2) and sent to BGI (BGI 145 
TechSolutions, China). BGI performed RNA extraction, RNA-sequencing (seq) and small 146 
RNA-seq (Illumina HiSeq 2000), filtered the reads to remove adaptors and low quality reads. 147 
RNA-seq reads aligned to reference genome (hg19; BWA v0.7.10-r789) were obtained from 148 
BGI and read counts per gene were enumerated using htseq-count (HTSeq v0.6.1p1 149 
(Anders et al, 2015); union of exons). Small RNA reads were obtained from BGI and aligned 150 
to microRNA (miRNA) mature sequences (MirBase v21 (Kozomara & Griffiths-Jones, 2011) 151 
using bowtie2 v2.2.5 (Langmead & Salzberg, 2012) with local alignment (--local –a). Read 152 
  
counts per miRNA were enumerated using reads which were uniquely mapped among 153 
reported alignments. Differential expression analyses from count data, and read count 154 
normalisation (rlog-transform) for visualisation and clustering, were performed using DESeq2 155 
v1.6.3 (Love et al, 2014). Differential expression analysis of HPV status was perfomed using 156 
DESeq2 with HPV status as the co-variable. Genes associated with hypoxic volume were 157 
identified using DESeq2 with hypoxic volume as a continuous co-variable. Gene set 158 
enrichment and leading edge analysis (GSEA v2.2.2 (Subramanian et al, 2005); pre-ranked 159 
tool; minimum set size=5; 1000 permutations) was performed on genes pre-ranked by fold-160 
change (per unit increase of hypoxic volume) and filtered for coverage (baseMean > 200). 161 
Gene sets with names containing the phrase 'hypoxia', 'HIF1' or 'HIF2' were pre-selected 162 
from all MSigDB curated gene sets (c2.all.v5.1.symbols.gmt (Subramanian et al, 2005)). 163 
Gene signature scores were estimated from normalised (rlog-transformed) read counts using 164 
a weighted sum of Z-scores for each gene in the respective gene list, with weights (+1,-1) 165 
according to the direction of expression in the original gene signature. 166 
 167 
Analysis of external gene expression data sets 168 
The following series were retrieved from the Gene Expression Omnibus (an international 169 
public genomics data repository): GSE686 (Chung et al, 2004) and GSE65858  (Wichmann 170 
et al, 2015). Follow-up information about progression-free survival (GSE65858) was 171 
obtained from GEO, and follow-up information about recurrence-free survival (GSE65858) 172 
was obtained from the original publication (Chung et al, 2004). A set of pre-defined 173 
exploratory analyses of follow-up were performed. Kaplan-Meier plots were used to inspect 174 
the hypoxic volume signature score by upper quartile, interquartile and lower quartile of the 175 
score values, samples in the upper quartile versus all other samples, and samples in the 176 
lower quartile versus all other samples. After inspection of the Kaplan-Meier plots, 177 
exploratory log-rank tests were performed for three year follow-up and for the whole follow-178 
up period, and hazard ratios were fitted to the same time periods using univariable Cox 179 
proportional hazards models. 180 
  
 181 
 182 
Statistical analysis 183 
Mann-Whitney U tests, Kaplan-Meier plots, log-rank tests and Cox proportional hazard 184 
model fits were performed in the R environment, v3.1.2 and ‘survival’ package v2.38 (R Core 185 
Team, 2014). Exact Wilcoxon-Mann-Whitney tests were performed using the ‘coin’ package 186 
v1.1-2. Cox models p-values report the Wald test. Unless otherwise stated, two-tailed tests 187 
are reported. P<0.05 was considered to be statistically significant.  188 
  
RESULTS 189 
 190 
Patient characteristics are summarised in Table 1. There were no immediate or late adverse 191 
reactions after tracer injection. Uptake was detected in all 15 primary tumours on 64Cu-ATSM 192 
PET scans (Figure 1A). Two patients had diagnostic tonsillectomies at diagnosis but uptake 193 
was seen in residual disease. The mean SUVmax for all 15 patients was 3.32 ± 0.85 (range 194 
2.12–4.85) and the mean TMR was 4.51 ± 1.82 (range 1.84–9.00) (Table 1). SUVmax and 195 
TMR were not significantly different between HPV-positive and HPV-negative patients. 196 
Tonsillectomy patients were excluded from analyses using hypoxic volume and SUVmean.  197 
 198 
 The mean hypoxic volume in 13 primary tumours was 12.54 cm3 ± 11.53 (range 199 
0.68–36.89) and the mean SUVmean was 2.34 ± 0.45 (range 1.71–3.11) (Table 1). 200 
Supplementary Figure S1 demonstrates examples of hypoxic volume delineation. Increased 201 
uptake was detected in 22 lymph nodes on 64Cu-ATSM PET scans out of 31 abnormal lymph 202 
nodes reported on CT imaging. Lymph node uptake appeared visually to be more 203 
heterogeneous than uptake in the primary tumour, especially in large nodes, which showed 204 
uptake in the periphery with central regions of no uptake, likely secondary to necrosis 205 
(Supplementary Figure S2). In general the uptake in the nodes was lower than the primary. 206 
The mean SUVmax of the nodes was 2.43 ± 0.93 (range 1.39–5.80) and the mean TMR 3.29 207 
± 2.41 (range 1.35–13.18) (Supplementary Table S1).   208 
 209 
 The differential gene expression between HPV-positive and HPV-negative samples 210 
were compared with previously published signatures (Keck et al, 2015; Pyeon et al, 2007) as 211 
an initial screen to assess the RNA sequencing from FFPE samples (Supplementary Figure 212 
S3). Overall the pattern of gene expression profiles in our HPV-positive versus HPV-213 
negative samples were readily distinguishable and consistent with previous studies. There 214 
was no difference in hypoxic volume, TMR or SUVmax between HPV-positive and HPV-215 
negative samples. 216 
  
 217 
 To establish whether RNA-seq data from the diagnostic biosies could report gene 218 
expression responses to hypoxia, we initially compared the gene expression of our samples 219 
with two different published hypoxia-associated signatures which have been used to assess 220 
hypoxia: a signature comprising genes regulated by hypoxia in head and neck cancers 221 
(Winter et al, 2007) and the 15-gene hypoxia classifier (Sorensen et al, 2015). There was 222 
high correlation between the two different signatures in our samples (Supplementary Figure 223 
S4C). Hypoxic volume was significantly associated with both the 15-gene hypoxia classifier 224 
(P=0.045; Spearman’s rho=0.57, two-tailed test, Figure 1D) and the Winter et al. gene list 225 
(P=0.05; Spearman’s rho=0.56, two-tailed test). SUVmax and TMR were not significantly 226 
associated with these hypoxia signatures; on inspection, four patient samples exhibited low 227 
scores for the 15-gene hypoxia signature but had among the highest values of SUVmax and 228 
TMR (Figure 1D). There were no significant differences in baseline characteristics between 229 
this ‘subgroup’ and the other samples, and these patients were amongst the oldest in the 230 
study (Mann-Whitney U, W=3, P=0.02).  231 
 232 
 To verify that hypoxic imaging volume and RNAseq-derived hypoxia gene expression 233 
response were associated with hypoxia in patient tumours, CA9 protein 234 
immunohistochemistry (IHC), a marker for hypoxia, was performed on biopsy samples.  235 
Among the image features, hypoxic volume showed a positive trend with CA9 IHC scores 236 
(Mann-Whitney U one-tailed, threshold median of hypoxic volume, P=0.06 (Figures 1B and 237 
S4A); Spearman’s rho=0.43, P=0.15 (Supplementary Figure S4A)). SUVmax and TMR were 238 
not associated with CA9 (Figures 1B and S4A). Furthermore, the 15-gene hypoxia classifier 239 
score was significantly associated with CA9 IHC scores (Spearman’s rho=0.63, P=0.01 240 
(Supplementary Figure S4B)). Genes ranked according to association with hypoxic volume 241 
were found to be enriched for previously curated hypoxia-associated gene sets with 242 
expression response to hypoxia or downstream of HIF-1 (Supplementary Table S2, 243 
Supplementary Figure S5). 244 
  
 245 
 The 15-gene hypoxia classifier (Sorensen et al, 2015) was originally derived and 246 
tested in multiple cancer types and may represent hypoxia gene expression responses that 247 
are commonly found across differing tumour types (Sorensen et al, 2015; Winter et al, 2007). 248 
We hypothesised that alternative gene signatures could accurately evaluate the hypoxic 249 
phenotypes in OPSCCs. We used the 64Cu-ATSM hypoxic volume together with mRNA 250 
expression from biopsy samples to identify a gene signature for hypoxic imaging phenotypes 251 
in OPSCCs. Hypoxic volume was significantly associated with increased expression of 16 252 
genes and decreased expression of five genes (hypoxic volume-associated gene signature, 253 
HVS) (Figure 2A, Supplementary Table S3). Two genes overlapped with the 15-gene 254 
hypoxia classifier, LOX and PFKFB3.  On inspection, there was concordance between the 255 
hypoxic volume-associated gene signature and expression of the 15-gene hypoxia classifier 256 
(Figure 2A). The HVS was more highly correlated with each of the image features (hypoxic 257 
volume, TMR and SUVmax) than the 15-gene hypoxia classifier, but only the hypoxic volume 258 
was significantly correlated with HVS (hypoxic volume: rho=0.89, P<10-4; TMR: rho=0.37, 259 
P=0.17; SUVmax: rho=0.45, P=0.09; Spearman’s correlation, two-tailed). Furthermore, the 260 
HVS was significantly associated with CA9 IHC staining (Mann-Whitney U one-tailed, 261 
threshold median of HVS score, P=0.03, Figure 2B). 262 
 263 
 To gain some initial insights into potential modes of gene regulation in tumours with a 264 
64Cu-ATSM imaging hypoxic phenotype, miRNAs were ranked according to the association 265 
of expression with increasing 64Cu-ATSM hypoxic volume. The top-ranked genes for 266 
association with the hypoxia volume signature were miR-21-5p (p=0.004, adjusted p=0.99) 267 
and miR-10b-5p (p=0.005, adjusted p=0.99) (Figure 2A, Supplementary Table S4). The 268 
study-derived HVS was then inspected in two publicly available data sets from head and 269 
neck cancers with long-term follow up and derived from alternative gene expression 270 
platforms; GEO series GSE686 (Chung et al, 2004), GSE65858 (Wichmann et al, 2015). 271 
The genes comprising the HVS were concordantly expressed within each data set 272 
  
(Supplementary Figure S6), which indicates that this signature may be widely relevant to 273 
head and neck tumour series. Finally, in exploratory analyses of each independent series, 274 
the HVS was found to be associated with poorer progression-free survival during a three 275 
year follow-up period (GSE65858; HR=1.5 [1.0-2.2], P=0.047) and there was a suggestive 276 
association with worse three-year recurrence-free survival (GSE686; HR=3.5 [0.8-16], 277 
P=0.1) (Supplementary Figure S6). 278 
 279 
 280 
DISCUSSION 281 
 282 
This study demonstrates that 64Cu-ATSM defined hypoxic volume correlates with a 283 
previously reported hypoxia gene expression response, and may be an important imaging 284 
parameter to consider for assessment of hypoxia in oropharyngeal squamous cell 285 
carcinomas (OPSCCs) using PET.  In addition, to describe the gene expression differences 286 
which underlie the PET imaging features, we identified a refined gene signature associated 287 
with 64Cu-ATSM hypoxic volume in OPSCCs. 288 
 289 
 64Cu-ATSM PET is well tolerated and demonstrates a spectrum of hypoxic imaging 290 
phenotypes in OPSCCs. Cu-ATSM has been investigated as a promising radiotracer for 291 
hypoxia imaging, which is a challenging area of research as hypoxia is spatially and 292 
temporally heterogeneous. Small clinical studies in HNSCC have reported that different 293 
imaging parameters correlate with progression or outcome, but there is currently no 294 
consensus, and the molecular mechanisms underlying these associations are not well 295 
understood. In addition, SUVmax, while widely reported, is a single voxel measure and may 296 
be sensitive to technical factors affecting PET (Adams et al, 2010). Minagawa et al. found 297 
that 62Cu-ATSM SUVmax, but not TMR, was significantly different in 17 locally advanced head 298 
and neck cancer patients with and without residual or recurrent tumours (Minagawa et al, 299 
2011). A study of 25 head and neck cancer patients indicated both increasing SUVmax and 300 
  
TMR were associated with worse progression-free survival (Sato et al, 2014). Grassi et al. 301 
(Grassi et al, 2014) used 64Cu-ATSM to define a biological target volume in 11 patients with 302 
HNSCC and found this parameter, along with SUVmax, to have high sensitivity but low 303 
specificity in predicting complete response to therapy. The same group reported that hypoxic 304 
tumour volume and hypoxic burden (hypoxic tumour volume x SUVmean) in 18 patients with 305 
lung cancer or HNSCC were more robust prognostic parameters for progression free 306 
survival after a median follow-up of 14.6 months (Lopci et al, 2015), which is in agreement 307 
with our data suggesting that hypoxic volume is an informative feature in 64Cu-ATSM PET 308 
scans. Our data suggest that hypoxic volume might be a more reliable correlate with gene 309 
expression patterns associated with hypoxia.  310 
 311 
 The optimal method for volume delineation is uncertain and requires further 312 
investigation. Grassi et al. (Grassi et al, 2014) used a cut off of 42% of the lesion SUVmax, 313 
but their subsequent study did not apply a fixed threshold for contouring (Lopci et al, 2015). 314 
The limited spatial resolution of PET makes defining the edge of tumour uptake difficult, but 315 
also means that PET imaging does not necessarily show the microregional, true 316 
heterogeneity of hypoxia within the tumour (Horsman et al, 2012). The mechanism of pO2 317 
dependence and factors that can affect cellular uptake and retention in both normoxic and 318 
hypoxic tissues is also unclear. Cu-ATSM may be an indirect marker for hypoxia, correlating 319 
with levels of the biological reductants NADH and NADPH (Yoshii et al, 2012). Hypoxia is 320 
one of a number of conditions leading to NADH accumulation, providing the cellular 321 
reduction potential which leads to tracer retention. Other factors such as multidrug 322 
resistance protein 1 (MDR1) expression (Liu et al, 2009) and CD133+ expression (Yoshii et 323 
al, 2012) have also been shown to influence Cu-ATSM uptake and retention, as well as 324 
cellular copper metabolism and processing (Hueting et al, 2014). Cu-ATSM is a promising 325 
radiotracer to detect hypoxia, but other possible sources of uptake need to be taken into 326 
consideration when interpreting the images and determining clinical utility.  327 
 328 
  
 We therefore inspected the genes comprising our proposed gene signature 329 
associated with hypoxic volume in OPSCCs. There were a number of upregulated genes 330 
relating to the development of hypoxia in tumours. For example, SOD2 is an antioxidant 331 
enzyme, which prevents redox-mediated damage of mitochondrial proteins, and is 332 
associated with aggressive cancers with enhanced cell migration and metastases. Stress 333 
such as hypoxia leads to increased reactive oxygen species (ROS) and tumours may 334 
increase their expression of SOD2 to prevent ROS-mediated DNA damage (Connor et al, 335 
2007). Also among the upregulated genes, NAMPT tissue expression has also been found 336 
to be upregulated in tumours and shown to induce cell proliferation and angiogenesis 337 
(Shackelford et al, 2013). It is the rate-limiting enzyme for the biosynthesis of NAD essential 338 
for metabolism and energy production. Tumour cells have high metabolic rate and NAD 339 
consumption and therefore depend on the production of NAD, and hypoxia has been shown 340 
to result in NAMPT induction (Bae et al, 2006). NAMPT small molecule inhibitors are under 341 
investigation as a novel therapeutic, which reduce NAD levels resulting in ATP loss and 342 
inhibition of tumour cell proliferation (Xu et al, 2015). RUNX3 is downregulated in our 343 
samples with increasing hypoxic volume. RUNX3 has been shown to inhibit HIF-1α stability 344 
through enhancing the interaction between HIF-1α and PHD2, promoting HIF-1α 345 
degradation in gastric cancer cells (Lee et al, 2014) with resulting inhibition of angiogenesis. 346 
Its expression has been shown to be downregulated in response to hypoxia and is frequently 347 
inactivated in gastric cancer, resulting in stimulation of proliferation and suppression of 348 
apoptosis (Lee et al, 2009). Supplementary Table S5 summarises the genes and their 349 
function. 350 
 351 
 CA9 is a transmembrane glycoprotein that is induced by hypoxia and considered an 352 
endogenous marker of hypoxia. It is a downstream target of hypoxia-inducible factor 1 (HIF-353 
1) in the hypoxia response pathway and has been shown to be overexpressed in HNSCC 354 
due to hypoxia (Beasley et al, 2001). The association between the hypoxic volume and CA9, 355 
and between the 15-gene hypoxia classifier and CA9, further suggests that hypoxic volume 356 
  
is an important feature for understanding hypoxic response in this series of OPSCCs, and 357 
that the gene expression from FFPE biopsy samples could reflect the hypoxia response of 358 
the tumour. 359 
 360 
 Among the miRNAs found to be associated with the hypoxic volume, miR-21 is 361 
frequently dysregulated miRNAs in HNSCC (Chang et al, 2008). Upregulation of miR-21 362 
promotes cell proliferation, migration and inhibition of apoptosis, and is associated with poor 363 
prognosis (Lu et al, 2008). Mir-210, the hypoxia miRNA (Huang et al, 2010), had low base 364 
coverage in our analysis and was not associated with hypoxia expression signatures.  365 
 366 
 This study had several limitations. First, there was a small sample size which is 367 
typical of exploratory imaging-genomic studies with patients recruited from a single 368 
institution. However, a strong point of our study is that the PET studies were performed and 369 
analysed in a standardised way at a single PET centre. Second, the validation of our 370 
hypoxia-associated signature was limited to in silico functional investigations in the absence 371 
of a clinical validation set, and warrants further study to elucidate the mechanisms 372 
underlying these associations. Third, Cu-ATSM as a radiotracer provides hypoxic-to-373 
normoxic contrast of sufficient quality to define a hypoxic volume but the optimal method for 374 
hypoxic volume delineation requires further investigation. Due to the existing clinical 375 
protocols for obtaining biopsy samples, it was not possible to attempt any registration 376 
(alignment) of biopsy sites and PET scans. Hypoxia responses detected in the diagnostic 377 
biopsy (CA9 hypoxia biomarker and gene expression profiling) were used to indicate the 378 
hypoxic status of the tumour, and more directly reflects clinical practise. These factors may 379 
be considered a limitation, and although outside the scope of this study, further work is 380 
needed to understand the effect of tumour heterogeneity on hypoxia evaluation in OPSCCs. 381 
 382 
 In conclusion, by combining PET imaging and mRNA expression profiling, our study 383 
revealed that Cu-ATSM PET hypoxic volume is associated with hypoxia gene signatures in 384 
  
OPSCCs and suggests that PET could be a useful surrogate for hypoxia gene signatures in 385 
order to stratify patients for treatment. As with all exploratory biomarker studies, our findings 386 
now require prospective investigation in a larger number of patients.   387 
 388 
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TITLES AND LEGENDS TO FIGURES 591 
 592 
Figure 1. 64Cu-ATSM PET imaging and association with CA9 immunohistochemical 593 
staining and a hypoxia gene expression response in disgnostic biopsies. A-B. 594 
Example images of 64Cu-ATSM PET (left) and fused PET/CT (right) scans. (A) Patient with 595 
T2N2b left base of tongue SCC, with Cu-ATSM uptake in the primary but no uptake in left 596 
level II neck node. (B) Patient with T3N1 left tonsil SCC with high uptake in primary. C. 597 
Immunohistochemistry staining of hypoxia biomarker CA9 versus each image feature. ‘High’ 598 
is defined as values greater than the median value. D. Scatterplots of 64Cu-ATSM imaging 599 
parameters versus the previously reported Sorensen2015 hypoxia classifier. Hypoxic 600 
volume, TMR and SUVmax plotted against the 15-gene hypoxia classifier. A significant 601 
positive correlation is observed between the hypoxia score and hypoxic volume, but not 602 
TMR or SUVmax. Red points indicate samples with low hypoxia score but high SUVmax. 603 
Samples from patients who had diagnostic tonsillectomies (Study IDs 9 and 11) were 604 
excluded as a hypoxic volume could not be determined. 605 
 606 
Figure 2. Hypoxia-associated gene signature (HVS) associated with hypoxic volume. 607 
A. The heatmap displays the HVS, comprising 16 genes positively and 5 genes negatively 608 
associated with hypoxic volume. Samples are ordered by increasing hypoxic volume (base 609 
mean > 200, adjusted P<0.05; or italicised: adjusted P<0.1. Two genes which overlapped 610 
with the 15-gene hypoxia classifier gene list are shown in bold. Yellow and blue colour bar 611 
shows the hypoxia 15-gene classifier score by rank within samples, for comparison 612 
(Sorensen2015). B. CA9 IHC is shown compared with ‘low’ or ‘high’ HVS signature scores 613 
for all samples (n=15). ‘High’ is defined as HVS scores greater than the median of HVS 614 
scores. 615 
Table 1. Patient baseline characteristics and uptake values
Study 
ID Gender Age T stage N stage HPV status SUVmax TMR
Hypoxic 
volume 
(cm3) SUVmean
Time, 
biopsy to 
imaging 
(days)
1 Female 51 2 2b Negative 2.57 2.64 9.78 1.96 21
4 Male 60 3 0 Positive 3.61 6.07 29.58 2.45 18
8 Male 71 4 2b Negative 3.96 9.00 5.60 2.46 38
9 Male 54 2 2b Positive 2.67 3.63 35
10 Male 46 4 0 Positive 3.14 3.74 6.31 2.02 34
11 Female 61 2 2a Positive 2.99 3.23 18
12 Male 64 2 2b Positive 4.35 5.61 10.76 3.11 41
13 Male 59 3 1 Positive 3.83 5.36 36.89 2.61 22
14 Male 47 3 2b Positive 3.34 5.91 7.55 2.27 24
15 Male 44 2 2c Negative 4.85 4.71 21.66 2.94 45
16 Male 66 3 2b Negative 3.75 5.00 23.01 2.58 13
17 Male 56 2 2a Positive 2.34 2.91 2.15 1.90 22
18 Male 69 1 2b Negative 2.12 2.83 0.68 1.71 30
19 Male 64 2 1 Positive 4.21 5.10 7.51 2.68 18
20 Female 60 1 2b Positive 2.13 1.84 1.49 1.77 25
Tumour to muscle ratio (TMR) is the ratio of SUVmax to average SUVmean of bilateral posterior neck muscle.
Hypoxic volume and SUVmean are excluded for tonsillectomy patients (Study IDs 9, 11).
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